[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f_p6RgvyI59oNB__dcmstwrr0EMs7DjgPhSH8UAZP5EQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Uniformed Services University of the Health Sciences",[4],45,false,14,1,14997,35,[13,16,19,22,25,27,29,31],{"name":14,"count":15},"Traumatic Brain Injury",9,{"name":17,"count":18},"PTSD",4,{"name":20,"count":21},"Nightmare",3,{"name":23,"count":24},"Healthy",2,{"name":26,"count":24},"Insomnia",{"name":28,"count":24},"Traumatic Brain Injury (TBI)",{"name":30,"count":24},"Obstructive Sleep Apnea (OSA)",{"name":32,"count":24},"Resilience",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07267819","Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents","2028-06-06","Xeomin",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,71,98,124,150,175,200,218,242,266,290,320,338,356,374],{"intervention":38,"totalTrials":9,"cells":48},{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":58,"NA":60},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":51},[],{"trials":59,"activeCount":51},[],{"trials":61,"activeCount":9,"soonestReadout":37},[62],{"nctId":35,"briefTitle":36,"status":63,"phases":64,"primaryCompletion":37,"completion":37,"start":65,"enrollment":66,"conditions":67,"interventions":70},"RECRUITING",[],"2025-08-05",60,[68,14,69],"Migraine","Anomalous Health Incidents",[38],{"intervention":72,"totalTrials":9,"cells":73},"Lidocaine topical",{"EARLY_PHASE1":74,"PHASE1":76,"PHASE2":78,"PHASE3":80,"PHASE4":82,"NA":96},{"trials":75,"activeCount":51},[],{"trials":77,"activeCount":51},[],{"trials":79,"activeCount":51},[],{"trials":81,"activeCount":51},[],{"trials":83,"activeCount":51},[84],{"nctId":85,"briefTitle":86,"status":87,"phases":88,"primaryCompletion":89,"completion":90,"start":91,"enrollment":92,"conditions":93,"interventions":95},"NCT05890495","Patient-Applied Pretreatment Analgesia for Intrauterine Device Placement","UNKNOWN",[44],"2023-12","2024-01","2023-06",120,[94],"Contraception",[72],{"trials":97,"activeCount":51},[],{"intervention":99,"totalTrials":9,"cells":100},"Ivabradine",{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":122},{"trials":102,"activeCount":51},[],{"trials":104,"activeCount":51},[],{"trials":106,"activeCount":51},[],{"trials":108,"activeCount":51},[],{"trials":110,"activeCount":51},[111],{"nctId":112,"briefTitle":113,"status":87,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":121},"NCT05481177","Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort",[44],"2024-09-01","2023-06-14",250,[119,120],"Long Haul COVID","Postural Orthostatic Tachycardia Syndrome",[99],{"trials":123,"activeCount":51},[],{"intervention":125,"totalTrials":9,"cells":126},"Riluzole",{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":144,"PHASE4":146,"NA":148},{"trials":128,"activeCount":51},[],{"trials":130,"activeCount":51},[],{"trials":132,"activeCount":51},[133],{"nctId":134,"briefTitle":135,"status":136,"phases":137,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":143},"NCT02155829","Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)","COMPLETED",[41,42],"2017-10-30","2017-11-30","2013-07",75,[17],[125],{"trials":145,"activeCount":51},[],{"trials":147,"activeCount":51},[],{"trials":149,"activeCount":51},[],{"intervention":151,"totalTrials":9,"cells":152},"Sildenafil",{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":169,"PHASE4":171,"NA":173},{"trials":154,"activeCount":51},[],{"trials":156,"activeCount":51},[],{"trials":158,"activeCount":51},[159],{"nctId":160,"briefTitle":161,"status":136,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":168},"NCT01762475","Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.",[42],"2015-12","2013-01",59,[14,167],"Post-concussive Syndrome",[151],{"trials":170,"activeCount":51},[],{"trials":172,"activeCount":51},[],{"trials":174,"activeCount":51},[],{"intervention":176,"totalTrials":9,"cells":177},"Sildenafil Citrate 50Mg Tab",{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":194,"PHASE4":196,"NA":198},{"trials":179,"activeCount":51},[],{"trials":181,"activeCount":51},[],{"trials":183,"activeCount":51},[184],{"nctId":185,"briefTitle":186,"status":187,"phases":188,"primaryCompletion":189,"completion":189,"start":190,"enrollment":9,"conditions":191,"interventions":192},"NCT04058132","Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military","TERMINATED",[42],"2020-03-01","2019-08-09",[14],[176,193],"Gadolinium contrast",{"trials":195,"activeCount":51},[],{"trials":197,"activeCount":51},[],{"trials":199,"activeCount":51},[],{"intervention":193,"totalTrials":9,"cells":201},{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":212,"PHASE4":214,"NA":216},{"trials":203,"activeCount":51},[],{"trials":205,"activeCount":51},[],{"trials":207,"activeCount":51},[208],{"nctId":185,"briefTitle":186,"status":187,"phases":209,"primaryCompletion":189,"completion":189,"start":190,"enrollment":9,"conditions":210,"interventions":211},[42],[14],[176,193],{"trials":213,"activeCount":51},[],{"trials":215,"activeCount":51},[],{"trials":217,"activeCount":51},[],{"intervention":219,"totalTrials":9,"cells":220},"methylphenidate",{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":236,"PHASE4":238,"NA":240},{"trials":222,"activeCount":51},[],{"trials":224,"activeCount":51},[],{"trials":226,"activeCount":51},[227],{"nctId":228,"briefTitle":229,"status":187,"phases":230,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":235},"NCT02148783","Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI",[42],"2018-08","2014-09",11,[14],[219],{"trials":237,"activeCount":51},[],{"trials":239,"activeCount":51},[],{"trials":241,"activeCount":51},[],{"intervention":243,"totalTrials":9,"cells":244},"Erythropoietin",{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":260,"PHASE4":262,"NA":264},{"trials":246,"activeCount":51},[],{"trials":248,"activeCount":51},[],{"trials":250,"activeCount":51},[251],{"nctId":252,"briefTitle":253,"status":254,"phases":255,"primaryCompletion":256,"completion":257,"start":232,"enrollment":51,"conditions":258,"interventions":259},"NCT02148367","Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI","WITHDRAWN",[42],"2016-06","2016-12",[14],[243],{"trials":261,"activeCount":51},[],{"trials":263,"activeCount":51},[],{"trials":265,"activeCount":51},[],{"intervention":267,"totalTrials":9,"cells":268},"N-acetylcysteine",{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":284,"PHASE4":286,"NA":288},{"trials":270,"activeCount":51},[],{"trials":272,"activeCount":51},[],{"trials":274,"activeCount":51},[275],{"nctId":276,"briefTitle":277,"status":254,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":51,"conditions":281,"interventions":283},"NCT04964843","A Study of NAC for AUD",[42],"2025-01","2023-04",[282],"Alcohol Use Disorder",[267],{"trials":285,"activeCount":51},[],{"trials":287,"activeCount":51},[],{"trials":289,"activeCount":51},[],{"intervention":291,"totalTrials":9,"cells":292},"Single dose rifaximin 1650 mg",{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":301,"NA":303},{"trials":294,"activeCount":51},[],{"trials":296,"activeCount":51},[],{"trials":298,"activeCount":51},[],{"trials":300,"activeCount":51},[],{"trials":302,"activeCount":51},[],{"trials":304,"activeCount":51},[305],{"nctId":306,"briefTitle":307,"status":187,"phases":308,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":315},"NCT01618591","Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea",[45],"2016-03","2012-09",384,[313,314],"Acute Watery Diarrhea","Dysentery\u002FFebrile Diarrhea",[291,316,317,318,319],"Single dose azithromycin 500 mg","Single dose levofloxacin 500 mg","Single dose azithromycin 1000 mg plus loperamide","Single dose azithromycin 1000 mg plus placebo",{"intervention":316,"totalTrials":9,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":330,"NA":332},{"trials":323,"activeCount":51},[],{"trials":325,"activeCount":51},[],{"trials":327,"activeCount":51},[],{"trials":329,"activeCount":51},[],{"trials":331,"activeCount":51},[],{"trials":333,"activeCount":51},[334],{"nctId":306,"briefTitle":307,"status":187,"phases":335,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":336,"interventions":337},[45],[313,314],[291,316,317,318,319],{"intervention":317,"totalTrials":9,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":350},{"trials":341,"activeCount":51},[],{"trials":343,"activeCount":51},[],{"trials":345,"activeCount":51},[],{"trials":347,"activeCount":51},[],{"trials":349,"activeCount":51},[],{"trials":351,"activeCount":51},[352],{"nctId":306,"briefTitle":307,"status":187,"phases":353,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":354,"interventions":355},[45],[313,314],[291,316,317,318,319],{"intervention":318,"totalTrials":9,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":368},{"trials":359,"activeCount":51},[],{"trials":361,"activeCount":51},[],{"trials":363,"activeCount":51},[],{"trials":365,"activeCount":51},[],{"trials":367,"activeCount":51},[],{"trials":369,"activeCount":51},[370],{"nctId":306,"briefTitle":307,"status":187,"phases":371,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":372,"interventions":373},[45],[313,314],[291,316,317,318,319],{"intervention":319,"totalTrials":9,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":384,"NA":386},{"trials":377,"activeCount":51},[],{"trials":379,"activeCount":51},[],{"trials":381,"activeCount":51},[],{"trials":383,"activeCount":51},[],{"trials":385,"activeCount":51},[],{"trials":387,"activeCount":51},[388],{"nctId":306,"briefTitle":307,"status":187,"phases":389,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":390,"interventions":391},[45],[313,314],[291,316,317,318,319]]